767-70-4

Basic information

• Product Name: Benzothiazole, 7-bromo- (7CI,8CI)
• Synonyms: 7-bromo-1,3-benzothiazole;7-broMobenzo[d]thiazole;Benzothiazole, 7-bromo- (7CI,8CI);7-Bromobenzothiazole
• CAS NO: 767-70-4
• Molecular Formula: C₇H₄BrNS
• Molecular Weight: 214.08236
• Product Categories: BENZOTHIAZOLE
• Mol File: 767-70-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 291.493 °C at 760 mmHg
• Flash Point: 130.09 °C
• Appearance: /
• Density: 1.748 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.718
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.42±0.30(Predicted)
• CAS DataBase Reference: Benzothiazole, 7-bromo- (7CI,8CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzothiazole, 7-bromo- (7CI,8CI)(767-70-4)
• EPA Substance Registry System: Benzothiazole, 7-bromo- (7CI,8CI)(767-70-4)

Safety Data

• Hazardous Substances Data: 767-70-4(Hazardous Substances Data)

Usage

General Description

Benzothiazole, 7-bromo- (7CI,8CI) is a chemical compound with the molecular formula C7H4BrNS. It is a substituted benzothiazole derivative with a bromine atom attached to the 7th carbon atom of the benzene ring. Benzothiazole, 7-bromo- (7CI,8CI) is used in the synthesis of pharmaceuticals, agrochemicals, and as an intermediate in organic synthesis. It is also used in the preparation of fluorescent dyes, optical brighteners, and as a corrosion inhibitor. Benzothiazole, 7-bromo- (7CI,8CI) is known for its potential biological activities and is of interest in medicinal chemistry for its antiviral, anticancer, and antimicrobial properties.

InChI:InChI=1/C7H4BrNS/c8-5-2-1-3-6-7(5)10-4-9-6/h1-4H

Upstream product

• 533-30-2 1,3-benzothiazol-6-amine 
• 769-20-0 6-amino-7-bromo-1,3-benzothiazole 
• 1123-55-3 7-amino-1,3-benzothiazole 

Downstream Products

• 882055-21-2 2-Bromo-7-(4-fluoro-phenyl)-benzothiazole 
• 882055-20-1 7-(4-Fluoro-phenyl)-2-thiophen-3-yl-benzothiazole 
• 882055-27-8 4-[7-(4-Fluoro-phenyl)-benzothiazol-2-yl]-thiophene-2-sulfonic acid 
• 882055-39-2 4-[7-(4-Fluoro-phenyl)-benzothiazol-2-yl]-thiophene-2-sulfonyl chloride 
• 20358-05-8 7-bromo-1,3-benzothiazol-2-amine 
• 1326714-48-0 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole 
• 882055-19-8 7-(4-fluoro-phenyl)-benzothiazole 
• 96426-78-7 benzothiazole-7-thiol 

Relevant articles and documents

Method for synthesizing benzothiazole by microwave radiation of benzothioamide compound in aqueous phase

The invention discloses a method for synthesizing benzothiazole by microwave radiation of a benzothioamide compound in an aqueous phase. The method includes the steps: adding the benzothioamide compound into the aqueous phase under microwave conditions; performing cyclization under alkaline conditions to generate the benzothiazole. The method for preparing the benzothiazole is environmentally friendly, simple and convenient in operation, safe, cheap and efficient. Compared with the prior art, the method is applicable to a lot of functional groups, high in yield, few in by-products, simple in operation, safe, low in cost and environmentally friendly.

Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)- thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors

4-(1,3-Benzothiazol-2-yl)thiophene-2-sulfonamide (4a) was found to be a moderately potent inhibitor of cyclin-dependent kinase 5 (cdk5) from a HTS screen. The synthesis and SAR around this hit is described. The X-ray coordinates of ligand 4a with cdk5 are also reported, showing an unusual binding mode to the hinge region via a water molecule.

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.